Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTWajeeh KhanTue, August 18, 2026 at 10:10 PM GMT+2 3 min readBiotechnology and medical scientific research by Brian A Jackson via ShutterstockAmylyx (AMLX) stock ripped higher on Tuesday after the pharmaceutical firm reported promising Phase 3 clinical trial data for its candidate drug, avexitide. In its press release, AMLX said its avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia, demonstrated a 55% reduction in hypoglycemic events in the Lucidity trial. More News from BarchartBarron Trump, 20, Now Worth $150 Million — More Than Mom, Melania — From Crypto And $39 Energy DrinkBillionaire Michael Saylor Warns Against Buying a House Because 'Every 36 Years You Actually Pay the Cost of the House in Tax to the Government'